Year All2024202320222021202020192018201720162015201420122011 Nov 15, 2023 XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia Nov 13, 2023 Ardelyx Announces Departure of Board Member Nov 10, 2023 Ardelyx to Participate at the Jefferies London Healthcare Conference Nov 6, 2023 Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States Nov 3, 2023 Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 Oct 31, 2023 Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Oct 30, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Oct 23, 2023 Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023 Oct 18, 2023 Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023 Oct 17, 2023 Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital